Compare Stocks

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADRO Aduro Biotech		$10.93	$4.51 ▼ $20.20	$236.61M	0.4	162,237 shs	171,500 shs
APTX Aptinyx	$0.10 +3.1%	$0.08	$0.01 ▼ $0.72	N/A	1.27	1.32 million shs	231,100 shs
KALV KalVista Pharmaceuticals	$11.50 -1.3%	$12.78	$7.21 ▼ $16.88	$485.19M	0.88	751,119 shs	408,653 shs
OPTN OptiNose	$0.93 -8.8%	$1.52	$0.90 ▼ $2.10	$104.51M	-0.24	534,927 shs	548,193 shs
SBBP Strongbridge Biopharma	$2.00	$2.09	$1.85 ▼ $4.26	$135.66M	1.58	866,464 shs	684,684 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADRO Aduro Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
APTX Aptinyx	0.00%	0.00%	0.00%	0.00%	-24.41%
KALV KalVista Pharmaceuticals	-1.94%	-2.35%	-2.84%	-6.50%	+47.47%
OPTN OptiNose	-6.42%	-18.40%	-47.29%	-22.14%	-49.75%
SBBP Strongbridge Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.9206 of 5 stars	3.5	1.0	0.0	4.6	2.7	2.5	0.6
OPTN OptiNose	3.6827 of 5 stars	3.5	3.0	0.0	4.2	0.0	2.5	0.6
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADRO Aduro Biotech	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.00	Buy	$26.33	128.99% Upside
OPTN OptiNose	3.00	Buy	$4.00	331.17% Upside
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ADRO, KALV, OPTN, SBBP, and APTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00
2/14/2024	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $24.00
2/13/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $35.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADRO Aduro Biotech	$17.26M	0.00	N/A	N/A	$4.07 per share	0.00
APTX Aptinyx	$1M	N/A	N/A	N/A	$0.57 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.71 per share	N/A
OPTN OptiNose	$70.99M	1.47	N/A	N/A	($0.77) per share	-1.20
SBBP Strongbridge Biopharma	$30.73M	4.41	N/A	N/A	$0.98 per share	2.04

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADRO Aduro Biotech	-$82.37M	-$5.15	N/A	N/A	N/A	-230.92%	-101.73%	-22.35%	N/A
APTX Aptinyx	-$64.85M	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	-$92.91M	-$3.15	N/A	N/A	N/A	N/A	-86.06%	-72.65%	7/5/2024 (Estimated)
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)
SBBP Strongbridge Biopharma	-$45.08M	-$0.78	N/A	N/A	N/A	-115.67%	-66.82%	-36.21%	N/A

Latest ADRO, KALV, OPTN, SBBP, and APTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/11/2024	Q3 2024	KALV KalVista Pharmaceuticals	-$0.75	-$0.84	-$0.09	-$0.84	N/A	N/A
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADRO Aduro Biotech	N/A	8.91	8.91
APTX Aptinyx	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	5.44	5.44
OPTN OptiNose	N/A	0.60	0.55
SBBP Strongbridge Biopharma	0.38	3.00	2.95

Ownership

Institutional Ownership

Company	Institutional Ownership
ADRO Aduro Biotech	49.93%
APTX Aptinyx	N/A
KALV KalVista Pharmaceuticals	N/A
OPTN OptiNose	85.60%
SBBP Strongbridge Biopharma	52.03%

Insider Ownership

Company	Insider Ownership
ADRO Aduro Biotech	5.90%
APTX Aptinyx	10.97%
KALV KalVista Pharmaceuticals	12.30%
OPTN OptiNose	2.20%
SBBP Strongbridge Biopharma	5.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADRO Aduro Biotech	152	16.21 million	N/A	Optionable
APTX Aptinyx	12	N/A	N/A	Not Optionable
KALV KalVista Pharmaceuticals	118	42.19 million	37.00 million	Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable
SBBP Strongbridge Biopharma	72	67.83 million	N/A	Optionable

ADRO, KALV, OPTN, SBBP, and APTX Headlines

Source	Headline
	Rising Investment in Patient Support Drives a Greater Biopharma Focus on Measurement fiercepharma.com - March 5 at 7:51 AM
	Matinas BioPharma Holdings Inc (MTNB) investing.com - February 10 at 12:33 PM
	Lytix Biopharma As Share Price (LYTIX.OL) lse.co.uk - November 15 at 2:21 AM
	Ambrx Biopharma Inc AMAM morningstar.com - November 4 at 7:36 PM
	Biopharma’s rapid transition to omnichannel marketing pharmaphorum.com - September 11 at 9:18 AM
	HILS Hillstream BioPharma, Inc. seekingalpha.com - August 19 at 3:55 PM
	ABUS - Arbutus Biopharma Corporation finance.yahoo.com - July 1 at 12:38 PM
	The Nominees for Best Biopharma CEO of 2015 Are... thestreet.com - April 25 at 8:23 AM
	Day One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenib marketwatch.com - January 11 at 9:43 PM
	Biopharma Soars to the Computational Clouds genengnews.com - October 9 at 12:47 PM
	Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients markets.businessinsider.com - September 22 at 10:04 AM
	Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ... apnews.com - September 23 at 5:49 PM
	Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc. finance.yahoo.com - September 23 at 5:49 PM
	Press Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma sharecast.com - September 14 at 5:56 PM
	Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma stockhouse.com - September 14 at 5:56 PM
	Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ... apnews.com - September 9 at 12:31 PM
	Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ... apnews.com - August 31 at 7:54 AM
	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeris tmcnet.com - August 31 at 7:54 AM
	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris finance.yahoo.com - August 31 at 7:54 AM
	Strongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen Next marketingsentinel.com - August 14 at 7:50 AM
	Strongbridge Biopharma: Q2 Earnings Snapshot sfgate.com - August 5 at 8:43 AM
	Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - August 5 at 8:43 AM
	Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement finance.yahoo.com - August 2 at 9:34 AM
	Strongbridge Biopharma plc (NASDAQ:SBBP) Shares Plunges -8.08% In A Week – But Can It Keep Rising? marketingsentinel.com - July 31 at 9:50 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aduro Biotech

NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Aptinyx

NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

KalVista Pharmaceuticals

NASDAQ:KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Strongbridge Biopharma

NASDAQ:SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial